Genomic Alterations in Lung and Thyroid Cancer: Expert Guidance in Incorporating Molecular Testing to Deliver Precision Therapy

Download All
In this multidisciplinary online program, experts provide guidance on the optimal management of lung or thyroid cancer with a genomic aberration in NTRK or RET, from testing to treatment. Watch on-demand webcasts of live meetings featuring the perspectives of medical oncologists, pathologists, and endocrinologists, and then download the corresponding slides along with an accompanying clinical resource PDF for use in your clinic.
Juan C. Hernandez-Prera, MD
Jeremy P. Segal, MD, PhD

ASCP 2022 Pathology Symposium

Download these slides from a live symposium at ASCP 2022 featuring guidance from a pathologist on best practices for biomarker testing in advanced thyroid cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET-altered and BRAF V600E–positive disease.

Juan C. Hernandez-Prera, MD Released: September 13, 2022

Download these slides from a live symposium at ASCP 2022 featuring guidance from a pathologist on best practices for detection of gene fusions in advanced non-small-cell lung cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET and NTRK fusion–positive disease.

Jeremy P. Segal, MD, PhD Released: September 14, 2022
Provided by Clinical Care Options, LLC in partnership with the American Society for Clinical Pathology.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Blueprint Medicines and Genentech, a member of the Roche Group
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings